First dose to first week Some users notice effects from the very first dose
Studies focused on traumatic brain injury recovery and aging models have used 48-hour interval protocols effectively, suggesting this represents near the minimum frequency that maintains cumulative neuroplastic stimulus
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
InjectCo prescribes GHK-Cu as a physician-supervised compounded topical formulation, the better delivery method for the skin and hair goals our patients come in with, from an FDA-registered 503A compounding pharmacy
GHK-Cu influences follicle cycling through multiple mechanisms including stimulation of VEGF and hepatocyte growth factor (HGF) secretion from hair follicle cells, with research demonstrating that advanced delivery formulations achieve ~3-fold enhancement of GHK-Cu penetration while retaining biological function and stimulating dermal papilla cells at the base of follicles